Phase II win for Silence's divesiran in PV lifts bar for Takeda's rusfertide on August 12, 2026 88% Clinical Response divesiran dosing Frequency of Responses Hepcidin mimetics NDA Perl50 Phase II SANRECO Polycythemia Priority Review siRNA therapy Takeda rusfertide Trimonthly Venous blood sampling vera PV +
Gene‑silencing drug divesiran posts strong Phase 2 win in rare blood cancer on August 11, 2026 divesiran gene-silencing Hematocrit procedure Hematologic Neoplasms Hepcidin Infrequent Polycythemia RNA, Small Interfering rusfertide SANRECO Silence Therapeutics ' Takeda TMPRSS6 gene Venous blood sampling Vera +